ZA9956B - Bisulfate salt of HIV protease inhibitor. - Google Patents

Bisulfate salt of HIV protease inhibitor.

Info

Publication number
ZA9956B
ZA9956B ZA9900056A ZA9956A ZA9956B ZA 9956 B ZA9956 B ZA 9956B ZA 9900056 A ZA9900056 A ZA 9900056A ZA 9956 A ZA9956 A ZA 9956A ZA 9956 B ZA9956 B ZA 9956B
Authority
ZA
South Africa
Prior art keywords
protease inhibitor
hiv protease
bisulfate salt
bisulfate
salt
Prior art date
Application number
ZA9900056A
Other languages
English (en)
Inventor
Janak Singh
Madhusudhan Pudipeddi
Mark D Lindrud
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22104737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA9956(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ZA9956B publication Critical patent/ZA9956B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA9900056A 1998-01-20 1999-01-05 Bisulfate salt of HIV protease inhibitor. ZA9956B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7196898P 1998-01-20 1998-01-20

Publications (1)

Publication Number Publication Date
ZA9956B true ZA9956B (en) 2000-07-05

Family

ID=22104737

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9900056A ZA9956B (en) 1998-01-20 1999-01-05 Bisulfate salt of HIV protease inhibitor.

Country Status (38)

Country Link
US (1) US6087383A (cs)
EP (1) EP1056722B1 (cs)
JP (2) JP4860037B2 (cs)
KR (1) KR100559283B1 (cs)
CN (1) CN1116282C (cs)
AR (1) AR014417A1 (cs)
AT (1) ATE219057T1 (cs)
AU (1) AU735875B2 (cs)
BG (1) BG64774B1 (cs)
BR (1) BR9814736A (cs)
CA (1) CA2317736C (cs)
CO (1) CO4970820A1 (cs)
CZ (1) CZ293507B6 (cs)
DE (1) DE69806067T2 (cs)
DK (1) DK1056722T3 (cs)
EE (1) EE04434B1 (cs)
EG (1) EG23936A (cs)
ES (1) ES2178300T3 (cs)
GE (1) GEP20033026B (cs)
HU (1) HU227196B1 (cs)
IL (2) IL137384A0 (cs)
LT (1) LT4780B (cs)
LV (1) LV12522B (cs)
MY (1) MY114838A (cs)
NO (1) NO315605B1 (cs)
NZ (1) NZ504417A (cs)
PE (1) PE20000185A1 (cs)
PL (1) PL190744B1 (cs)
PT (1) PT1056722E (cs)
RO (1) RO118869B1 (cs)
RU (1) RU2186070C2 (cs)
SK (1) SK283975B6 (cs)
TR (1) TR200001876T2 (cs)
TW (1) TW531531B (cs)
UA (1) UA59432C2 (cs)
UY (1) UY25345A1 (cs)
WO (1) WO1999036404A1 (cs)
ZA (1) ZA9956B (cs)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE302751T1 (de) 2000-06-30 2005-09-15 Elan Pharm Inc Verbindungen zur behandlung der alzheimerischen krankheit
EP1392645A2 (en) * 2001-05-22 2004-03-03 Elan Pharmaceuticals, Inc. Aza hydroxylated ethyl amine compounds
US7157561B2 (en) * 2001-07-13 2007-01-02 Roche Diagnostics Operations, Inc. Methods of inhibiting transmission of a costimulatory signal of lymphocytes
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
AU2004206821C1 (en) * 2003-01-14 2009-10-01 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
CN101565398B (zh) * 2004-05-04 2011-12-14 布里斯托尔-迈尔斯斯奎布公司 制备阿扎那韦硫酸氢盐的方法和新的形式
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
US20050256314A1 (en) * 2004-05-04 2005-11-17 Soojin Kim Process employing controlled crystallization in forming crystals of a pharmaceutical
US20050288343A1 (en) * 2004-05-19 2005-12-29 Andrew Rusowicz Process of preparing substituted carbamates and intermediates thereof
TWI354569B (en) 2004-05-28 2011-12-21 Bristol Myers Squibb Co Coated tablet formulation and method
BRPI0518741A2 (pt) * 2004-12-03 2008-12-02 Merck & Co Inc uso de uma combinaÇço de uma droga diretamente metabolizada por ugt1a1 ou um seu sal farmaceuticamente aceitÁvel e atazanavir ou um seu sal farmaceuticamente aceitÁvel, e, combinaÇço farmacÊutica para administraÇço oral a um mamÍfero
US7642049B2 (en) * 2006-06-30 2010-01-05 Bristol-Myers Squibb Company Method for identifying HIV-1 protease inhibitors with reduced metabolic affects through detection of human resistin polymorphisms
US7723380B2 (en) * 2006-07-21 2010-05-25 Gilead Sciences, Inc. Antiviral protease inhibitors
BG66056B1 (bg) * 2006-10-05 2010-12-30 Красимир ДЕЧЕВ Метод и инсталация за производство на трисезонна добавка към дизелово гориво
EP2116532B1 (en) * 2007-06-12 2011-12-07 Concert Pharmaceuticals, Inc. Azapeptide derivatives as HIV protease inhibitors
ES2360336T3 (es) * 2007-06-22 2011-06-03 Bristol-Myers Squibb Company Composiciones en comprimidos que contienen atazanavir.
EP2170292B1 (en) * 2007-06-22 2014-01-08 Bristol-Myers Squibb Holdings Ireland Tableted compositions containing atazanavir
KR20100033377A (ko) * 2007-06-22 2010-03-29 브리스톨-마이어스 스큅 컴퍼니 아타자나비르를 함유하는 정제 조성물
CN101778625A (zh) * 2007-06-22 2010-07-14 百时美施贵宝公司 含有阿扎那韦的压片组合物
MX2009013828A (es) * 2007-06-29 2010-03-10 Gilead Sciences Inc Composiciones terapeuticas y su uso.
CN101686972B (zh) * 2007-06-29 2013-08-14 吉里德科学公司 治疗用组合物和方法
US20110178305A1 (en) * 2008-05-08 2011-07-21 Ranbaxy Laboratories Limited Process for the preparation of 3,4-epoxy-2-amino-1-substituted butane derivatives and intermediate compounds thereof
EP2391350A1 (en) 2008-12-18 2011-12-07 Ranbaxy Laboratories Limited Atazanavir formulations
EP2376452A4 (en) 2009-01-12 2012-08-29 Hetero Research Foundation NEW SULFATE POLYMORPH OF ATAZANAVIR
JP2012528160A (ja) 2009-05-27 2012-11-12 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｉｖプロテアーゼ阻害薬
EP2272830A1 (en) 2009-06-18 2011-01-12 Esteve Química, S.A. Preparation process of an antivirally heterocyclic azahexane derivative
WO2011027324A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Polymorphic forms of atazanavir sulfate
PL2493312T3 (pl) 2009-10-26 2022-01-03 Merck Sharp & Dohme Corp. Kompozycje farmaceutyczne w postaci ciała stałego zawierające inhibitor integrazy
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
SMT201800290T1 (it) 2010-01-27 2018-07-17 Viiv Healthcare Co Terapia antivirale
US20130005780A1 (en) 2010-03-01 2013-01-03 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
WO2011127244A2 (en) 2010-04-09 2011-10-13 Bristol-Myers Squibb Company ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
EA201390464A1 (ru) 2010-09-28 2013-08-30 Рациофарм Гмбх Способ сухой обработки атазанавира
WO2013014633A1 (en) 2011-07-27 2013-01-31 Ranbaxy Laboratories Limited Process for preparation of atazanavir or its bisulfate salt
US8461347B2 (en) 2011-08-05 2013-06-11 Scinopharm Taiwan, Ltd. Process for preparing form A of atazanavir sulfate
WO2013059928A1 (en) 2011-10-26 2013-05-02 Merck Canada Inc. Hiv protease inhibitors
EP2888230A4 (en) * 2012-08-24 2017-07-19 Laurus Labs Private Limited Improved process for the preparation of atazanavir bisulfate
WO2014036690A1 (zh) * 2012-09-04 2014-03-13 上海迪赛诺化学制药有限公司 制备阿扎那韦硫酸氢盐a型结晶的方法
US9890121B2 (en) 2013-02-12 2018-02-13 Cipla Limited Process for preparing atazanavir sulphate
CN104250224A (zh) * 2013-06-28 2014-12-31 上海威智医药科技有限公司 阿扎那韦富马酸盐及其制备和应用
CN104250225A (zh) * 2013-06-28 2014-12-31 上海威智医药科技有限公司 阿扎那韦磷酸盐及其制备和应用
CN104250223B (zh) * 2013-06-28 2017-04-12 上海威智医药科技有限公司 阿扎那韦氢溴酸盐及其制备和应用
CN105859611A (zh) * 2016-04-18 2016-08-17 上海现代制药海门有限公司 一种阿扎那韦硫酸氢盐a型结晶的制备方法
CN109251165B (zh) * 2018-10-02 2022-09-23 国药集团川抗制药有限公司 阿扎那韦达二4-氨基苯磺酸盐及其制备方法
CN111349042B (zh) * 2018-12-20 2023-07-14 陕西理工大学 一种阿扎那韦单晶及其制备方法
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI933472A7 (fi) * 1992-08-07 1994-02-08 Sankyo Co Peptider med foermaoga att inhibera effekten av HIV-proteas, deras framstaellning och terapeutiska anvaendning
US5849911A (en) * 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives

Also Published As

Publication number Publication date
CA2317736A1 (en) 1999-07-22
IL137384A0 (en) 2001-07-24
UA59432C2 (uk) 2003-09-15
EP1056722A4 (en) 2001-01-10
SK283975B6 (sk) 2004-06-08
UY25345A1 (es) 2000-12-29
ES2178300T3 (es) 2002-12-16
KR100559283B1 (ko) 2006-03-15
PT1056722E (pt) 2002-09-30
NO20003692L (no) 2000-07-19
IL137384A (en) 2006-08-01
EE200000798A (et) 2002-06-17
HUP0101389A3 (en) 2003-07-28
EP1056722A1 (en) 2000-12-06
RU2186070C2 (ru) 2002-07-27
BR9814736A (pt) 2000-10-24
CZ20002564A3 (cs) 2000-10-11
MY114838A (en) 2003-01-31
CA2317736C (en) 2004-11-02
CZ293507B6 (cs) 2004-05-12
DK1056722T3 (da) 2002-09-30
US6087383A (en) 2000-07-11
AU735875B2 (en) 2001-07-19
EP1056722B1 (en) 2002-06-12
JP2002509136A (ja) 2002-03-26
DE69806067D1 (de) 2002-07-18
HUP0101389A2 (hu) 2001-08-28
NO20003692D0 (no) 2000-07-19
PL190744B1 (pl) 2006-01-31
DE69806067T2 (de) 2003-01-23
JP4860037B2 (ja) 2012-01-25
LT4780B (lt) 2001-04-25
RO118869B1 (ro) 2003-12-30
BG64774B1 (bg) 2006-03-31
AU2010199A (en) 1999-08-02
GEP20033026B (en) 2003-07-25
HU227196B1 (en) 2010-10-28
KR20010034221A (ko) 2001-04-25
TW531531B (en) 2003-05-11
EG23936A (en) 2008-01-14
HK1033667A1 (en) 2001-09-14
CO4970820A1 (es) 2000-11-07
CN1116282C (zh) 2003-07-30
TR200001876T2 (tr) 2000-11-21
BG104618A (en) 2001-02-28
WO1999036404A1 (en) 1999-07-22
LV12522A (en) 2000-08-20
CN1283188A (zh) 2001-02-07
NZ504417A (en) 2001-09-28
PE20000185A1 (es) 2000-05-14
NO315605B1 (no) 2003-09-29
PL342019A1 (en) 2001-05-07
ATE219057T1 (de) 2002-06-15
SK10622000A3 (sk) 2001-02-12
JP2009102357A (ja) 2009-05-14
EE04434B1 (et) 2005-02-15
HK1033458A1 (en) 2001-08-31
LV12522B (en) 2000-10-20
LT2000067A (en) 2000-11-27
AR014417A1 (es) 2001-02-28

Similar Documents

Publication Publication Date Title
ZA9956B (en) Bisulfate salt of HIV protease inhibitor.
ZA992447B (en) Quinoxalinones as serine protease inhibitors.
PL349192A1 (en) Protease inhibitors
PL347948A1 (en) Serine protease inhibitor
ZA9811830B (en) Prodrugs of aspartyl protease inhibitors.
ZA992448B (en) Quinoxalinones as serine protease inhibitors.
ZA983629B (en) Serine protease inhibitors
EP1093367A4 (en) PROTEASE INHIBITORS
IL139187A0 (en) Cysteine protease inhibitors
EP1067894A4 (en) PROTHEASEINHIBITOREN
IS5531A (is) Grindarmálmpróteasa latar
EP1079821A4 (en) PROTEASE INHIBITORS
GB9800817D0 (en) Serine protease inhibitors
EP1086083A4 (en) PROTEASE INHIBITORS
EP1140897A4 (en) PROTEASE INHIBITORS
ZA984514B (en) Hiv protease inhibitor
ZA200007084B (en) Novel salts of N-tert-butylhydroxylamine.
IL132998A0 (en) Vif-derived hiv protease inhibitors
MXPA03004542A (es) Inhibidores de proteasa.
AU2001280634A1 (en) Salt forms of an hiv protease inhibitor
MXPA99008395A (es) Inhibidores de la proteasa del vih.
GB9714320D0 (en) Hiv protease inhibitor
EP1195163A4 (en) Serine protease inhibitors
PH31405A (en) Hiv protease inhibitors.
HK1038559A (en) Serine protease inhibitor